

***EXAMINER'S AMENDMENT***

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

***Claim Amendments***

2. The application has been amended as follows:

Claims 2-5 and 80 have been replaced by the following:

Claim 2. A substantially purified salivary *Phlebotomus ariasi* polypeptide, wherein the polypeptide comprises: a) residues 23-312 of the SEQ ID NO: 11; b) an amino acid sequence that is at least 95% identical to residues 23-312 of SEQ ID NO: 11; or c) an immunogenic fragment comprising at least fifteen contiguous amino acids of residues 23-312 of SEQ ID NO: 11.

Claim 3. A substantially purified salivary *Phlebotomus ariasi* polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to residues 23-312 of SEQ ID NO: 11.

Claim 4. A substantially purified salivary *Phlebotomus ariasi* polypeptide of claim 3, wherein the polypeptide comprises an amino acid sequence at least 99% identical to residues 23-312 of SEQ ID NO: 11.

Claim 5. An immunogenic fragment of the polypeptide of claim 4, wherein the immunogenic fragment comprises at least fifteen contiguous amino acids of residues 23-312 of SEQ ID NO: 11.

Art Unit: 1645

Claim 80. A substantially purified salivary *Phlebotomus ariasi* polypeptide of claim 4, wherein the polypeptide comprises residues 23-312 of SEQ ID NO: 11.

3. Claim 99 has been added:

Claim 99. A substantially purified salivary *Phlebotomus ariasi* polypeptide of claim 3, wherein the polypeptide comprises an amino acid sequence at least 98% identical to residues 23-312 of SEQ ID NO: 11.

### ***Conclusion***

4. Claims 2-5, 25, 80-81, 95, 97, and 99 are allowed and are renumbered as Claims 1-10 respectively.

Claims 27-33, 35-36, 82-94, and 96 are cancelled.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nina A. Archie whose telephone number is 571-272-9938. The examiner can normally be reached on Monday-Friday 8:30-5:00p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi can be reached on 571-272-0956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nina Archie  
GAU 1645  
REM 3B31

/Robert B Mondesi/  
Supervisory Patent Examiner, Art Unit 1645

Application/Control Number: 10/527,500  
Art Unit: 1645

Page 4